Zhaojin Mining has successfully solved the technical difficulties in deepsea deep well construction through the application of TBM technology, which is the first of its kind in the world. This has not only improved the company's mining efficiency, but also contributed to the technological progress of the global gold mining industry.
Zhaojin Mining has a sufficiently strong industrial background and has advantages in resource acquisition, market expansion and other aspects. Especially in the context of increasingly scarce global gold resources, Zhaojin Mining can rely on the group's rich resource network to further consolidate and expand its position in the global gold mining industry.
In this regard, institutions generally have a positive view on Zhaojin Mining. For example, UBS reports that Zhaojin Mining's profit compound annual growth rate from to will reach , revealing its strong confidence in the nigeria phone number list company's performance growth. In addition, institutions such as Citi and Goldman Sachs have also given higher target prices, reflecting the market's expectations for the future development of Zhaojin Mining.
It can be said that in a market full of uncertainty, Zhaojin Mining has brought a relatively more certain choice to the market with its strong industrial resource background and technological innovation capabilities.
Innovent Biologics Announces Approval of Second Indication for ROS Inhibitor Dabryl® Taretinib Adipate Capsules for FullLine Treatment of ROSPositive Lung Cancer
SAN FRANCISCO, U. and SUZHOU, China, Jan. , PRNewswire Innovent Biologics, Inc. HKEX: , a worldclass biopharmaceutical company engaged in the research, development, manufacturing and commercialization of innovative medicines for major diseases such as oncology, autoimmunity, metabolism, and ophthalmology, announced that the second New Drug Application NDA of DABOLE® taretinib adipate capsules, a nextgeneration ROS tyrosine kinase inhibitor TKI, has been approved by the China National Medical Products Administration NMPA for the treatment of adult patients with ROSpositive locally advanced or metastatic nonsmall cell lung cancer NSCLC.